Skip to Content

Kisqali Femara Co-Pack Dosage

Generic name: LETROZOLE 2.5mg; RIBOCICLIB 200mg
Dosage form: kit

Medically reviewed on May 4, 2017.

Dosing and Administration

The KISQALI FEMARA CO-PACK is comprised of ribociclib tablets copackaged with letrozole tablets, to provide a 28-day treatment regimen.

The KISQALI FEMARA CO-PACK should be coadministered, with or without food, as follows:

  • KISQALI: The recommended starting dose for KISQALI is 600 mg (three 200 mg tablets) taken orally, once daily for 21 consecutive days followed by 7 days off KISQALI treatment resulting in a complete cycle of 28 days.
  • FEMARA: 2.5 mg (one tablet) taken once daily throughout the 28-day cycle.

Patients should take their doses of KISQALI FEMARA CO-PACK at approximately the same time each day, preferably in the morning. If the patient vomits after taking the dose or misses a dose, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time. Tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.

For additional information on KISQALI® and FEMARA®, refer to the Full Prescribing Information for each product.

Dose Modifications

Dose Modifications for Adverse Reactions

The recommended dose modifications of KISQALI for adverse reactions are listed in Table 1.

Dose modifications are not recommended for FEMARA when administered with KISQALI for the adverse reactions of KISQALI, including: neutropenia, hepatobiliary toxicity, or QT prolongation [see Dosage and Administration (2)].

Table 1: Recommended Dose Modification of KISQALI FEMARA CO-PACK for Adverse Reactions
Level KISQALI FEMARA
Dose Number of Tablets Dose Number of Tablets
Starting dose 600 mg/day three 200 mg tablets 2.5 mg/day one 2.5 mg tablet
First dose reduction 400 mg/day two 200 mg tablets 2.5 mg/day one 2.5 mg tablet
Second dose reduction 200 mg/day* one 200 mg tablet 2.5 mg/day one 2.5 mg tablet
* If further dose reduction below 200 mg/day is required, discontinue KISQALI

Tables 2, 3, 4 and 5 summarize recommendations for dose interruption, reduction, or discontinuation of KISQALI in the management of specific adverse reactions. Dose modifications of KISQALI FEMARA CO-PACK are recommended based on individual safety and tolerability.

Table 2: Dose Modification and Management of KISQALI for Neutropenia
Neutropenia Grade 1 or 2
(ANC 1000/mm3 – <LLN)
Grade 3
(ANC 500 - <1000/mm3)
Grade 3 febrile* neutropenia Grade 4
(ANC <500/mm3)
No dose adjustment is required. Dose interruption until recovery to Grade ≤ 2. Resume KISQALI at the same dose level. If toxicity recurs at Grade 3, dose interruption until recovery, then resume KISQALI at the next lower dose level. Dose interruption until recovery of neutropenia to Grade ≤ 2. Resume KISQALI at the next lower dose level. Dose interruption until recovery to Grade ≤ 2. Resume KISQALI at the next lower dose level.
Perform Complete Blood Counts (CBC) before initiating treatment with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.
*Grade 3 neutropenia with single episode of fever >38.3°C (or) above 38°C for more than one hour and/or concurrent infection.
Grading according to CTCAE Version 4.03. CTCAE=Common Terminology Criteria for Adverse Events.
ANC = absolute neutrophil count; LLN = lower limit of normal
Table 3: Dose Modification and Management of KISQALI for Hepatobiliary Toxicity
AST and/or ALT elevations from baseline*, WITHOUT increase in total bilirubin above 2 x ULN Grade 1
(> ULN – 3 x ULN)
Grade 2
(>3 to 5 x ULN)
Grade 3
(>5 to 20 x ULN)
Grade 4
(>20 x ULN)
No dose adjustment is required. Baseline* at < Grade 2:
Dose interruption until recovery to ≤ baseline grade, and then resume KISQALI at same dose level. If Grade 2 recurs, resume KISQALI at next lower dose level.
-----------------------------
Baseline* at Grade 2:
No dose interruption.
Dose interruption until recovery to ≤ baseline* grade, then resume at next lower dose level. If Grade 3 recurs, discontinue KISQALI. Discontinue KISQALI
Combined elevations in AST and/or ALT WITH total bilirubin increase, in the absence of cholestasis If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue KISQALI.
Perform Liver Function Tests (LFTs) before initiating treatment with KISQALI.
Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.
If Grade ≥2 abnormalities are noted, more frequent monitoring is recommended.
*Baseline = prior to treatment initiation.
Grading according to CTCAE Version 4.03.
ULN = upper limit of normal
AST = aspartate aminotransferase; ALT = alanine aminotransferase
Table 4: Dose Modification and Management of KISQALI for QT Prolongation
ECGs with QTcF > 480 msec
  1. Interrupt KISQALI Treatment
  2. If QTcF prolongation resolves to < 481 msec, resume treatment at the same dose level;
  3. If QTcF ≥ 481 msec recurs, interrupt dose until QTcF resolves to < 481 msec; then resume KISQALI at next lower dose level.
ECGs with QTcF > 500 msec
  1. Interrupt KISQALI treatment if QTcF greater than 500 msec on at least 2 separate ECGs (within the same visit).
  2. If QTcF prolongation resolves to < 481 msec, resume treatment at the next lower dose level
Permanently discontinue KISQALI if QTcF interval prolongation is either greater than 500 msec or greater than 60 msec change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia.
Electrocardiograms (ECGs) should be assessed prior to initiation of treatment. Repeat ECGs at approximately Day 14 of the first cycle and at the beginning of the second cycle, and as clinically indicated.
In case of (QTcF) prolongation at any given time during treatment, more frequent ECG monitoring is recommended.
Table 5: Dose Modification and Management of KISQALI for Other Toxicities*
Other toxicities Grade 1 or 2 Grade 3 Grade 4
No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Dose interruption until recovery to Grade ≤1 then resume KISQALI at same dose level. If Grade 3 recurs, resume KISQALI at the next lower dose level. Discontinue KISQALI.
*Excluding neutropenia, hepatobiliary toxicity and QT interval prolongation.
Grading according to CTCAE Version 4.03.

Dose Modification for Use with Strong CYP3A Inhibitors

Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition [see Drug Interactions (7.1)]. If a strong CYP3A inhibitor must be coadministered, reduce the KISQALI dose to 400 mg once daily. If the strong inhibitor is discontinued, change the KISQALI dose (after at least 5 half-lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Dose Modification for Hepatic Impairment

No dose adjustment of KISQALI is necessary in patients with mild hepatic impairment (Child-Pugh class A). The recommended starting dose is 400 mg KISQALI once daily for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Clinical Pharmacology (12.3)].

No dose adjustment of FEMARA is necessary in patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment. The dose of FEMARA in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Clinical Pharmacology (12.3)]. The recommended dose of FEMARA for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined [see Clinical Pharmacology (12.3)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide